I’ve posted extensively on the various Lovenox scenarios, so I won’t repeat that discussion here. For the non-Lovenox components of MNTA’s business, I try to place a value on each of a set of hypothetical companies that owned one component of MNTA’s asset estate and nothing else. For modeling purposes, I use the following numbers:
Estimated AssetValue ($ Mln) Worldwide rights to M118 150
50% of NVS-MNTA Copaxone collaboration 250
Worldwide rights to M402 50
Worldwide rights to MNTA’s proprietary technology for all applications other than Lovenox/Copaxone/M118/M402 600
Net cash 70
*NOL’s 0* =========================== ===== All non-Lovenox assets 1,120
*I ascribe no separate value to the NOL’s because I consider them integral to MNTA’s Lovenox asset.
JMHO, FWIW
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.